Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Other
  • 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease
  • Other

223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease

Rare Disease Audio

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Antn Blatnik, PhD, who recently won a $150,000 grant from Cure SMA to study the molecular mechanisms that drive neuromuscular d

Neuroscience

Read full story

pharminent May 4, 2026 (Last updated: May 4, 2026)

Rare Disease Audio

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Antn Blatnik, PhD, who recently won a $150,000 grant from Cure SMA to study the molecular mechanisms that drive neuromuscular d

Neuroscience

Read full story

Post navigation

Previous: Eli Lilly to Acquire Kelonia Therapeutics
Next: Celcuity strengthens case for ASCO-spotlighted breast cancer drug

Related Stories

  • Other

Takeda and Weave Bio collaborate on AI-driven automation in drug development

pharminent September 2, 2026
  • Other

ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

pharminent June 2, 2026
  • Other

ASCO26: Symptom-tracking app helps advanced cancer patients

pharminent June 2, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.